Samalizumab
Samalizumab
Samalizumab (pronunciation: sa-ma-li-zu-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is an experimental drug that targets the immune system's regulatory cells, aiming to enhance the body's natural ability to fight cancer.
Etymology
The name "Samalizumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Sama-" does not have a specific meaning and is used for distinction.
Mechanism of Action
Samalizumab works by inhibiting the function of regulatory T cells, a type of white blood cell that suppresses the immune response. By blocking these cells, Samalizumab allows the immune system to more effectively attack cancer cells.
Clinical Trials
Samalizumab has been tested in several clinical trials for its effectiveness against various types of cancer, including leukemia, lymphoma, and melanoma. The results of these trials have been promising, but further research is needed to confirm its safety and efficacy.
Related Terms
- Monoclonal antibody
- Cancer
- Immune system
- Regulatory T cells
- Clinical trial
- Leukemia
- Lymphoma
- Melanoma
External links
- Medical encyclopedia article on Samalizumab
- Wikipedia's article - Samalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski